Jade Biosciences: Caution Advised Before Clinical Trial Results [Seeking Alpha]
Jade Biosciences, Inc. (JBIO)
Company Research
Source: Seeking Alpha
I rate JBIO a Hold due to binary risk: success could increase the share price, but failure in key trials could cause severe downside or bankruptcy. JADE101's femtomolar affinity offers 750x potency over competitors, but JBIO is years behind rivals like Otsuka's Voyxact, facing significant execution and market risks. JBIO's $88M cash and $247.7M short-term investments provide runway to 2028, but further equity raises are likely before expected revenue in 2029. Solskin/DigitalVision via Getty Images Jade Biosciences ( JBIO ) is a pre-revenue company that develops therapies for inflammation and patients with autoimmune diseases. Their biggest asset is JADE101, which targets the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for the treatment of immunoglobulin A (lgA) nephropathy (a chronic, progressive kidney disease). This
Show less
Read more
Impact Snapshot
Event Time:
JBIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JBIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JBIO alerts
High impacting Jade Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
JBIO
News
- Jade Biosciences (JBIO) had its "buy" rating reaffirmed by HC Wainwright.MarketBeat
- Jade Biosciences (JBIO) was upgraded by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from "sell (d-)" to "sell (d)".MarketBeat
- Jade Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Jade Biosciences Appoints Edward R. Conner, M.D., as Chief Medical OfficerGlobeNewswire
- Jade Biosciences (JBIO) had its "sell (d-)" rating reaffirmed by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
JBIO
Earnings
- 11/13/25 - Beat
JBIO
Sec Filings
- 4/27/26 - Form SCHEDULE
- 4/22/26 - Form 8-K
- 4/17/26 - Form PRE
- JBIO's page on the SEC website